• 2:16

  Studying patients at risk of dementia and defining subjective cognitive decline

  Ondrej Lerch

  Ondrej Lerch, MD from Charles University in Prague, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic introduces…
• 3:31

  ALS and frontotemporal dementia: on a continuum or part of a spectrum of disorders?

  Manuela Neumann

  Manuela Neumann, MD from the University Hospital Tuebingen, Tuebingen, Germany discusses the question of whether amyotrophic lateral sclerosis (ALS) and…
• 1:02

  Investigating physical activity and Alzheimer’s disease

  Kristian Steen Frederiksen

  Kristian Steen Frederiksen, MD, PhD from the Danish Dementia Research Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark discusses studies looking…
• 1:17

  Pioglitazone for the treatment of Alzheimer’s disease

  Daniela Galimberti

  Daniela Galimberti, PhD from the University of Milan, Milan, Italy discusses a study on pioglitazone for the treatment of Alzheimer's…
• 3:13

  Basal forebrain atrophy and elevated plasmatic homocysteine levels

  Ondrej Lerch

  Ondrej Lerch, MD from Charles University in Prague, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic talks…
• 2:23

  The effects of physical activity on Alzheimer’s disease biomarkers

  Kristian Steen Frederiksen

  Kristian Steen Frederiksen, MD, PhD from the Danish Dementia Research Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark discusses a systematic…
• 3:11

  A novel biomarker of Alzheimer’s disease progression: LTP-like cortical plasticity

  Francesco Di Lorenzo

  Francesco Di Lorenzo, MD from the Santa Lucia Foundation IRCCS, Rome, Italy gives an overview of a study investigating LTP-like…
• 1:38

  The neuropathology and genetics of ALS and FTD

  Manuela Neumann

  Manuela Neumann, MD from the University Hospital Tuebingen, Tuebingen, Germany provides an overview of the neuropathology and genetics of amyotrophic…
• 2:41

  Ethical considerations of biomarker use in prodromal Alzheimer’s disease

  Giovanni Frisoni

  There are currently no approved preventive or disease-modifying therapies available for Alzheimer’s disease. At the 2nd Congress of the European…
• 4:32

  The landscape of biomarkers for the management of Alzheimer’s disease

  Giovanni Frisoni

  At the 2nd Congress of the European Academy of Neurology (EAN), held in Copenhagen, Denmark, from May 28–31 2016, Giovanni…